<DOC>
	<DOC>NCT01808768</DOC>
	<brief_summary>To study the impact of alcaftadine in patients treated with other opthalmic ocular agents (or specific topical opthalmic treatment) in an allergy subspecialist outpatient setting.</brief_summary>
	<brief_title>Ocular Allergy Treatment Practical Impact Trial</brief_title>
	<detailed_description>To assess the impact of ocular allergy treatment on patients using an ophthalmic agent (or no treatment) versus alcaftadine(Lastacaft™)</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis, Allergic</mesh_term>
	<mesh_term>Alcaftadine</mesh_term>
	<criteria>1. patients age 18 and older with a history of seasonal or perennial forms of allergic conjunctivitis and skin test positive reactivity to seasonal aeroallergens 2. Total Ocular Symptom Score (TOSS) on the day of enrollment of 4 or more. 3. have allergic ocular symptoms for the past week for which they are either treating with ophthalmic agents or have had no treatment. 4. Are willing/able to follow instructions from the study investigator and his/her study staff. 5. Have signed infromed consent approved by Institutional Review Board or Independent Ethics Committee. 1. Active ocular infection; 2. History of retinal detachment, diabetic neuropathy, or any progressive retinal disease; 3. Ocular surgical intervention within three (3) months prior to visit 1 or scheduled during the study. 4. History of unstable, or uncontrolled disease of any nature. 5. Pregnancy or lactation; 6. Have a known hypersensitivity tp LASTACAFT™ (alcaftadine)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>